Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
SB	A9	2002/0061518	5/28/02	Penny and Galvin	435	6	5/05/99
	A10	2003/0077629	4/24/03	Galvin *et al.*	435	6	7/24/02
	A11	2003/0099960	5/29/03	Ratain *et al.*	435	6	1/25/02
	A12	2003/0099977	5/29/03	Guida and Kurth	435	6	7/26/02
	A13	2003/0157517	8/21/03	Penny and Galvin	435	6	9/18/02
	A14	2004/0058363	3/25/04	Hasegawa *et al.*	435	6	6/12/03
	A15	2004/0076968	4/22/04	Acuna *et al.*	435	6	7/02/01
	A16	2004/0121327	6/24/04	Manns and Strassburg	435	6	1/03/02
	A17	2004/0203034	10/14/04	Ratain *et al.*	435	6	1/05/04
	A18	5,972,614	10/1999	Ruano *et al.*	436	6	
	A19	6,448,003	9/10/2	Guida and Kurth	435	6	6/08/99
SB	A20	6,586,175	7/01/03	Galvin *et al.*	435	6	7/20/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B6	JP 2004-073035	3/11/04	Japan			Abstract
	B7	EP 1352970	10/15/03	Europe			English
	B8	WO 01/79230	10/25/01	WIPO			English
	B9	WO 02/053770	7/11/02	WIPO			English
	B10	WO 02/057410	7/25/02	WIPO			English
	B11	WO 02/06523	1/24/02	WIPO			English
	B12	WO 2003/013536	2/20/03	WIPO			English
SB	B13	WO 2003/013537	2/20/03	WIPO			English

25507126.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B14	WO 2004/016814	2/26/04	WIPO			Abstract
SB	B15	WO 97/32042	9/04/97	WIPO			English
SB	B16	WO 99/57322	11/11/99	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C218	Ando *et al.*, "UGTIA1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan," *Annals of Oncology*, 9:845-847, 1998.
SB	C219	Beutler *et al.*, "Racial variability in the UDP-glucuronosyltransferase 1(UGTIA1) promoter: a balanced polymorphism for regulation of bilirubin metabolism," *Proc. Natl. Acad. Sci., USA*, 95:8170-8174, 1998.
SB	C220	Clarke *et al.*, "Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-hemolytic unconjugated hyperbilirubinemias," Clinica Chimica Acta, 266:63-74, 1997.
SB	C221	De Morais *et al.*, "Decreased glucuronidation and increased bioactivation of Acetaminophen in Gilbert's syndrome," *Gastroenterology*, 102:577-586, 1992.

25507126.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
SB	A1	5,786,344	7/28/98	Ratain *et al.*	514	100	4/17/95
	A2	6,066,645	5/23/00	Hausheer *et al.*	514	283	1/6/99
	A3	6,287,834	9/11/01	Belanger *et al.*	435	193	2/08/99
	A4	6,319,678	11/20/01	Trubetskoy and Shaw	435	15	6/25/99
	A5	6,395,481	5/28/02	Di Rienzo *et al.*	435	6	1/16/99
	A6	6,407,117	6/18/02	Bouscarel *et al.*	514	283	3/23/00
	A7	6,472,157	10/29/02	De Rienzo and Ratain	435	6	2/01/02
	A8	6,479,236	11/12/02	Penny and Galvin	435	6	5/05/99

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
SB	B1	EP 0919244	6/2/99	Europe			Abstract
SB	B2	WO 00/06776	2/10/00	PCT			
SB	B3	WO 94/22846	10/94	PCT			
SB	B4	WO 95/08986	4/6/95	PCT			
SB	B5	WO 96/01127	1/18/96	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C1	Abraham *et al.*, "Non-glucocorticoid steriod analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine," *Cancer Chemother. Pharmacol.*, 32(2):116-122, 1993.
SB	C2	Akiyama *et al.*, "Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of p-glycoprotein by a vinblastine analog," *Mol. Pharmacol.*, 33(2):144-147, 1988.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C3	Ando *et al.*, "Polymorphisms of UDP-glycuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis," *Cancer Res.*, 60(24):6921-6926, 2000.
	C4	Ansher *et al.*, "Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity," *Hepatology*, 3(6):932-935, 1983.
	C5	Araki *et al.*, "Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11," *Jpn J. Cancer Res.*, 84:697-702, 1993.
	C6	Ariyoshi *et al.*, "Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein," *Jpn. J. Cancer Res.*, 83(5):515-521, 1992.
	C7	Atsumi *et al.*, "Identification of the Metabolites of Irinotecan, a New Derivative of Camptothecin, in Rat Bile and its Biliary Excretion," *Xenobiotica*, 21(9):1159-1169, 1991.
	C8	Barbier *et al.*, "3'-azido-3'-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 3B7 (UGT2B7)," *Drug Metab. Dispos.*, 28:497-502, 2000.
	C9	Barker *et al.*, "Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy," *J Chromatogr B Biomed Appl*, 681:323-329, 1996.
	C10	Bear, "Drugs transported by-P-glycoprotein inhibit a 40pS outwardly rectifying chloride channel," *Biochem. Biophys. Res. Commun.*, 200(1):513-521, 1994.
	C11	Bell *et al.*, "Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin," *Biochem. Pharmacol.*, 48(3):495-503, 1994.
	C12	Bertrand *et al.*., "Sequential Administration of Camptothecin and Etoposide Circumvents the Antagonistic Cytotoxicity of Simultaneous Drug Administration in Slowly Growing Human Colon Carcinoma HT-29 Cells," *Eur. J. Cancer*, 28A(4-5):743-748, 1992.
	C13	Beutler *et al.*, "Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism," *PNAS USA*, 95(14):8170-8174, 1998.
SB	C14	Bhasker *et al.*, "Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance," *Pharmacogenetics*, 10(8):679-685, 2000.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C15	Bible and Kaufmann, "Cytotoxic synergy between flavopiridol (NSSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration," *Cancer Res.*, 57:3375-3380, 1997.
	C16	Bible and Kaufmann, "Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells," *Cancer Res.*, 56:4856-4861, 1996.
	C17	Bock *et al.*, In: Conjugation reactions in biotransformation, Elsevier, North Holland Biomedical Press, p. 357-364, 1978.
	C18	Boesch and Loor, "Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents," *Anticancer Drugs*, 5(2):229-238, 1994.
	C19	Boesch *et al.*, "Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative," *Exp. Cell. Res.*, 196(1):26-32, 1991.
	C20	Boiteux-Antoine *et al.*, "Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds," *Gen-Pharmacol*, 20(4):407-412, 1989.
	C21	Bosma *et al.*, "Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar Syndrome, Type I," *Hepatology*, 15:941-947, 1992.
	C22	Bosma *et al.*, "The genetic basis of the reduced expression of bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's Syndrome," *N. Eng. J. Med.*, 333:1171-1175, 1995.
	C23	Burchell and Coughtrie, "UDP-glucuronosyltransferases," *Pharmac. Ther.*, 43:261-289, 1989.
	C24	Burchell *et al.*, "The UDP Glucuronosyltransferase gene suprefamily: suggested nomenclature based on evolutionary divergence, *DNA cell biol.*, 10:487-494, 1991.
	C25	Burger *et al.*, "Pharmacokinetic interaction between rifampin and zidovudine," *Antimicrobial Agents and Chemotherapy*, 37(7):1426-1431, 1993.
	C26	Campain *et al.*, "Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II," *J. Cell Physiol.*, 155(2):414-425, 1993.
SB	C27	Carlson *et al.*, "Flavopiridol induces G^1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells," *Cancer Res*, 56:2973-2978, 1996.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C28	Carrier *et al.*, "Isolation and characterization of the human UGT2B7 gene," *Biochem and Biophys. Res. Commun.*, 272:616-621, 2000.
	C29	Cascorbi et al., "Frequency of single nucleotide polymorphisms in the p-glycoprotein drug transporter MDR1 gene in white subjects," *Clinc. Pharmacol Ther.*, 69:169-174, 2001.
	C30	Charuk *et al.*, "Interaction of Rat Kidney P-Glycoprotein with a Urinary Component and Various Drugs Including Cyclosporin A," *Am. J. Physiol.*, 266:F66-F75, 1994.
	C31	Chen *et al.*, "Fluorescence polarization in homogeneous nucleic acid analysis," *Genome Res.*, 9:492-498, 1999.
	C32	Chen *et al.*, "Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA," *Biotechniques*, 6:632-638, 1988.
	C33	Cheng *et al.*, "Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7," *Toxicological Sciences*, 45:52-57, 1998.
	C34	Chien *et al.*, "In vitro evaluation of flavopiridol, a novel cell cycle inhibitor, in bladder cancer," *Cancer Chemother Pharmaco*, 44:81-87, 1999.
	C35	Chin *et al.*, "Reduced mRNA levels for multidrug-resistance genes in cAMP-dependent protein kinase mutant cell lines," *J. Cell Physiol.*, 152(1):87-94, 1992.
	C36	Clarke and Burchell, "The Uridine Diphosphate glucuronosyltransferase multigene family: function and regulation," *Handbook of experimental pharmacology*, 112:3-43, 1994.
	C37	Coffman *et al.*, "Cloning and stable expression of a cDNA encoding a rate liver UDP-Glucuronosyltransferase (UDP_Glucuronosyltransferase 1.1) that catalyzes the glucuronidation of opiods and bilirubin," *Mol. Pharmacol.*, 47:1101-1105, 1995.
	C38	Coffman *et al.*, "Human UGT2B7 catalyzes morphine glucuronidation," *Drug Metab Dispos.*, 25:1-4, 1997.
	C39	Coffman *et al.*, "The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268)," *Drug Metab Dispos*, 26:73-77, 1998.
	C40	Cordon-Cardo *et al.*, "Expression of the multidrug resistant gene product (P-glycoprotein) in human normal and tumor tissues," *J. Histochem. Cytochem.*, 38:1277-1287, 1990.
SB	C41	Czech *et al.*, "Antitumoral activity of flavone L86-8275," *Int J Oncol*, 6:31-66, 1995.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C42	Davies and Schnell, "Oltipraz-induced amelioration of acetaminophen hepatotoxicity in hamseters," *Toxicology and Applied Pharmacology*, 109:29-40, 1991.
	C43	de Forni *et al.*, "Phase I and pharmacokinetic study of the camptothecin derivative irinotecan administered on a weekly schedule in cancer patients," *Cancer Res.*, 54:4347-4354, 1994.
	C44	De Lannoy *et al.*, "Cyclosporin and Quinidine Inhibition of Renal Digoxin Excretion: Evidence for Luminal Secretion of Digoxin," *Am. J. Physiol*, 263:F613-F622, 1992.
	C45	De Morais *et al.*, "Biotransformation and Toxicity of Acetaminophen in Congenic RHA Rats with or without a Hereditary Deficiency in Bilirubin UDP-Glucuronosyltransferase," *Toxicology and Applied Pharmacology*, 117:81-87, 1992.
	C46	Decleves et al., "A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encloding the P-glycoprotein," *Human Mutation*, 15: 486, 2000.
	C47	Dhainaut *et al.*, "New Triazine Derivatives as Potent Modulators of Multidrug Resistance," *J. Med. Chem.*, 35:2481-2496, 1992.
	C48	Di Carlo *et al.*, "Flavonoids: old and new aspects of a class of natural therapeutic drugs," *Life Sci*, 65:337-353, 1999.
	C49	Di Rienzo *et al.*, "Two new alleles in the promoter of the bilirubin UDP-glucuronosyl transferase 1 (UGT1A1) gene", *American Society for Clinical Pharmacology and Therapeutics*, Ninety Ninth Annual Meeting, New Orleans, Abstract OII-B-3, page 207, 1998.
	C50	Diasio et al., "Clinical pharmacology of 5-fluorouracil," *Clin Pharmacokinet*, 16:215-237, 1989.
	C51	Dobbs and Twelves, "What is the effect of adjusting epirubicin doses for body surface area?" *British Journal of Cancer*, 78(5):662-666, 1998.
	C52	Doige *et al.*, "ATPase activity of partially purified P-glycoprotein from multidrug-resistant chinese hamster ovary cells," *Biochim. Biophys. Acta.*, 1109(2):149-160, 1992.
	C53	Drees *et al.*, "Flavopiridol (86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells," *Clin Cancer Res*, 3:273-279, 1997.
SB	C54	Egner *et al.*, "Regulation of Phase 2 Enzyme Induction by Oltipraz and other Dithiolethiones," *Carcinogenesis*, 15(2):177-181, 1994.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C55	Ewesuedo and Ratain, "Topoisomerase I inhibitors," *Oncologist*, 2(6):359-364, 1997.
	C56	Evans and Relling, "Automated high-performance liquid chromatographic assay for the determinationof 7-ethoxycoumarin and umbelliferone," *J. Chromatogr.*, 578:141-145, 1992.
	C57	Ford *et al.*, "Cellular and biochemical characterization of thioxanthenes for reversal of multidrug resistance in human and murine cell lines," *Cancer Res.*, 50(6):1748-1756, 1990.
	C58	Fournel *et al.*, "Structure-dependent induction of bilirubin glucuronidation and lauric acid 12-hydroxylation by arylcarboxylic acids chemically related to clofibrate," *Biochimica at Biophysica Acta*, 842:202-213, 1985.
	C59	Foxwell *et al.*, "Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein," *Mol. Pharmacol.*, 36:543-546, 1989.
	C60	Friche *et. al.*, "In vitro circumvention of anthracycline-resistance in ehrlich ascites tumour by anthracycline analogues" *Biochem. Pharmacol.*, 39:1721-1726, 1990.
	C61	GenBank Accession Number AF297093.
	C62	GenBank Accession Number NM_001074.
	C63	Gestl *et al.*, "Expression of UGT2B7, a UDP-glucuronosyltransferase implicated in the metabolism of 4-hydroxyestrone and all-trans retinoic acid, in normal human breast parenchyma and in invasive and in Situ breast cancers," *American Journal of Pathology*, 160(4):1467-1479, 2002.
	C64	Gram *et al.*, "Clinical relevance of gentic polymorphisms in drug oxidation," *Clinical Relevance of Genetic Polymorphisms in Drug Oxidation*, 1992.
	C65	Green *et al.*, "Expressed human UGT1.4 protein catalyzes the formation of quaternary ammonium-linked glucuronides," *Drug Metab. Dispos.*, 23:299-302, 1995.
	C66	Gruol *et al.*, "Reversal of multidrug resistance by RU 486[1]" *Cancer Res.*, 54(12):3088-3091, 1994.
	C67	Guillamette *et al.*, "Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans," *Cancer Res.*, 60:950-956, 2000.
SB	C68	Gunn, "Hereditary Acholuric Jaundice," *J. Hered.*, 29:137-139, 1938.

25389367.1

EXAMINER:	/Sarae Bausch/	DATE CONSIDERED:	07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C69	Gupta *et al.*, "Metabolic Fate of Irinotecan in humans: Correlation of Glucuronidation with Diarrhea," *Cancer Res.*, 54:3723-3725, 1994.
	C70	Gupta *et al.*, "Pharmacokinetic and pharmacodynamic evaluation of the topisomerase inhibitor Irinotecan in cancer patients," *J. Clin. Oncol.*, 15:1502-1510, 1997.
	C71	Gupta *et al.*, "Modulation of glucoronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital, *Cancer Chemother. Pharmacol.*, 39(5):440-444, 1997.
	C72	Gupta *et al.*, "Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A., *Cancer Res.*, 56(6):1309-1314, 1996.
	C73	Gupta *et al.*, "Role of carboxyl esterase in the metabolism of CPT-11, a camptothecin analog, in humans" *Pharm. Res.*, 11:S450, 1994.
	C74	Gutmann *et al.*, "Modulation of multidrug resistance protein expression in porcine brain capillary endothelial cells in vitro," *Drug Metab Dispos.* 27:937-941, 1999.
	C75	Hait *et al.*, "Terferadine (seldane®): a new drug for restoring sensitivity to multidrug resistant cancer cells" *Biochem. Pharmacol.*, 45(2):401-406, 1993.
	C76	Hamada *et al.*, "Mouse-human chimeric antibody against the multidrug transporter P-glycoprotein" *Cancer Res.*, 50(11):3167-3171, 1990.
	C77	Harding *et al.*, "Cloning and substrate specificity of a human phenol UDP-glucuronosyltransferase expressed in COS-7 cells," *PNAS, USA*, 85:8381-8385, 1988.
	C78	Hecht *et al.*, "4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and its glucuronide, metabolites of a tobacco-specific lung carcinogen, in the urine of black and white smokers," *Proceedings of the American Association for Cancer Research*, 35:1702, 1994.
	C79	Hendricks *et al.*, "Effect of P-Glycoprotein Expression on the Accumulation and Cytotoxicity of Topotecan (SK&F 104864), a New Campotthecin Analogue," *Cancer Research*, 52:2268-2278, April 1992.
	C80	Hjelle, "Hepatic UDP-Glucuronic Acid Regulation during Acetaminophen Biotransformation in Rats," *The Journal of Pharmacology and Experimental Therapeutics*, 237(3):750-756, 1986.
SB	C81	Hoffmeyer *et al.*, "Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations an dcorrelation of one allele with p-glycoprotein expression and activity in vivo," *PNAS*, 28:97(7):3473-3478, 2000.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C82	Holthe *et al.*, "Morphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1a1*28 polymorphisms in cancer patients on chronic morphine therapy," *European Journal of Clinical Pharmacology*, 58: 353-356, 2002.
	C83	Hooijberg *et al.*, "Potent interaction of flavopiridol with MRP1," *British J. of Cancer*, 81:269-276, 1999.
	C84	Hsu *et al.*, "Universal SNP genotyping assay with fluorescence polarization detection," *BioTechniques*, 31:560-570, 2001.
	C85	Hunter *et al*, "Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial caco-2 cell layers" *Pharm. Res.*, 10(5):743-749, 1993.
	C86	Ichikawa-Haraguchi *et al.*, "Progesterone and its metabolites: the potent inhibitors of the transporting activity of P-glycoprotein in the adrenal gland" *Biochim. Biophys. Acta*, 1158(3):201-208, 1993.
	C87	Innocenti *et al.*, "Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan," *Drug Metab. Dispos.*, 29(4 pt 2):596-600, 2001.
	C88	Innocenti *et al.*, "Pharmacogenetics: a tool for individualizing antineoplastic therapy," *Clin. Pharmacokinet.*, 39(5):315-325, 2000.
	C89	Innocenti *et al.*, "Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyl transferase 2B7," *Drug Metab. Dispos.*, 29(5):686-692, 2001.
	C90	Innocenti *et al.*, "Epirubicin is glucuronidated by UGT2B7," *Clinical Pharmacology and Therapeutics*, 67(2):100, Abstract PI-44, 2000.
	C91	Innocenti et al., "Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea," *Clinical Cancer Research*, 6:3400-3405, 2000.
	C92	Innocenti *et al.*, "Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups," *Pharmacogenetics J.*, 12(9):725-733, 2002.
	C93	Inoue *et al.*, "Cellular detoxification of tripeptidyl aldehydes by an aldo-keto reductase" *J. Biol. Chem.*, 268(8):5894-5898, 1993.
	C94	Ishii *et al.*, "Octamer transcription factor-1 enhances hepatic nuclear factor-1 α-mediated activation of the human UDP glucuronosyltransferase 2B7 promoter," *Molecular Pharmacology*, 57:940-947, 2000.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C95	Ito et al., "Polymorphism of the abc transporter genes mdr1, mrp1 and mrp2/cmoat, in healthy japanese subjects," *Pharmacogenetics,* 11:175-184, 2001.
	C96	Iyer and Ratain, "Pharmacogenetics and cancer chemotherapy," *Eur J Cancer*, 34:1493-1499, 1998.
	C97	Iyer *et al.*, "Genetic basis for the glucuronidation of SN-38: Role of UGT*1 isoform," *Clinical Pharmacology and Therapeutics*, 61:Abstract, 1997.
	C98	Iyer *et al.*, "Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucoronosyltransferase isoform 1A1 in the glucouronidation of its active metabolite (SN-38) in human liver microsomes," *J. Clin. Invest.*, 101(4):847-854, 1998.
	C99	Iyer *et al.*, "Glucuronidation of TAS-103 by uridine diphosphate glucuronosyltransferase (UGT) isoforms 1a1 and 2: possible implication of TAS-103 toxicity in Gilbert's syndrome," *Ann Oncol* 9(Supplement 2):61, abstract #230, 1998.
	C100	Iyer *et al.*, "UGT isoform 1.1 (UGT*1.1) glucuronidates SN-38, the active metabolite of irinotecan," *Program Proceedings of the American Society of Clinical Oncology*, 16:Abstract, 1997.
	C101	Iyer *et al.*, "Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan and bilirubin glucoronidation in human liver tissue with UGT1A1 promoter polymorphism," *Clin. Phamacol. Ther.*, 65(5):576-582, 1999.
	C102	Iyer, "Inherited variations in drug-metabolizing enzymes: significance in clinical oncology," *Mol Diagnosis,* 4:327-333, 1999.
	C103	Iyer *et al.*, "UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity," *Pharmacogenetics J.*, 2(1):43-47, 2002.
	C104	Iyer *et al.*, "Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice," *Cancer Chemother. Pharmacol.*, 49(4):336-341, 2002.
	C105	Jager *et al.*, "Metabolism of the anticancer drug vlavopiridol, a new inhibitor of cyclin dependent kinases in rat liver," *Life Sci.,* 62:1861-1873, 1998.
SB	C106	Jin *et al.*, "cDNA cloning and expression of two new members of the human glucuronosyltransferase 2B subfamily," *Biochem. Biphys. Res. Comm.*, 194(1):496-503, 1993.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C107	Jin *et al.*, "Complementary deoxyribonucleic acid cloning and expression of human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs," *J. Pharm. Experim. Therap.*, 264(1):475-479, 1993.
	C108	Kamimoto *et al.*, "The function of GP-170, the multidrug resistant gene product, in rat liver canalicular membrane vesicles," *J. Biol. Chem.*, 264:11693-11698, 1989.
	C109	Kamiwatari *et al.*, "Correlation between reversing of multidrug resistance and inhibiting of [^{3}H]azidopine photolabeling of P-glycoprotein by newly synthesized dihydrophyridine analogues in a human cell line," *Cancer Res.*, 49(12):3190-3195, 1989.
	C110	Kaneda *et al.*, "Metabolism and Pharmacokinetics of the campothecin analogue CPT-11 in the mouse," *Cancer Res.*, 50:1715-1720, 1990.
	C111	Kano *et al.*, "Effects of CPT-11 in Combination with Other Anti-Cancer Agents in Culture," *Int. J. Cancer*, 50(4):604-610, 1992.
	C112	Karato *et al.*, "Phase I Study of CPT-11 and Etoposide in Patients with Refractory Solid Tumors," *J. Clin. Oncol.*, 11(10):2030-2035, 1993.
	C113	Kaufmann, "Antagonism Between Camptothecin and Topoisomerase II-Directed Chemotherapeutic Agents in a Human Leukemia Cell Line," *Cancer Res.*, 51(4):1129-1136, 1991.
	C114	Kaur *et al.*, "Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275," *J Natl Cancer Inst.*, 84:1736-1740, 1992.
	C115	King *et al.*, "The Glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-Glucuronosyltransferase 1.1," *Arch. Biochem. Biophys.*, 332:92-100, 1996.
	C116	Kiue *et al.*, "Activities of newly synthesized dihydropyridines in overcoming of vincristine resistance, calcium antagonism, and inhibition of photoaffinity labeling of P-glycoprotein in rodents," *Cancer Res.*, 50(2):310-317, 1990.
	C117	Klein *et al.*, "An inventory of the human ABC proteins," *Bioch Biophys Acta*, 1461:237-262, 1999.
SB	C118	Klein *et al.*, "Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucoronide," *Clin. Pharmacol. Ther.*, 72(6):638-647, 2002.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C119	Kusuhara *et al.*, "Reduced folate derivatives are endogenous substrates for cmoat in rats," *Am J Physiol.*, 275(4 Pt 1):G789-G796, 1998.
	C120	Lampe *et al.*, "Prevalence of polymorphisms in the human UDP-glucuronosyltransferase 2B family: UGT2B4(D458E), UGT2B7(H268Y), and UGT2B15(D85Y)," *Cancer Epidemiology, Biomarkers and Prevention, american Association for Cancer Research*, 9:329-333, 2000.
	C121	Lennard *et al.*, "Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism," *Clin. Pharmacol. Ther.*, 46:149-154, 1989.
	C122	Lennard, "The clinical pharmacology of 6-mercaptopurine," *Eur J Clin Pharmacol*, 43:329-339, 1992.
	C123	Levesque *et al.*, "Characterization and substrate specificity of UGT2B4 (E^{458}: a udp-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics*, 9:207-216, 1999.
	C124	Levesque *et al.*, "Isolation and characterization of UGT2B15(Y^{85}): a UDP-glucuronosyltransferase encoded by a polymorphic gene," *Pharmacogenetics*, 7:317-325, 1997.
	C125	Lokeic *et al.*, "Pharmacokinetics of irinotecan and its metabolites in human blood, bile and urine," *Cancer Chemother. Pharmacol.*, 36:79-82, 1995.
	C126	Lomri *et al.*, "Hepatocellular transport: role of atp-binding cassette proteins," *Semin. Liv. Dis.*, 16: 201-210, 1996.
	C127	Losiewicz *et al.*, "Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275," *Biochem Biophys Res Commun*, 201:589-595, 1994.
	C128	Lubet *et al.*, "A Pleiotropic Response to Phenobarbital-Type Enzyme Inducers in the F344/NCr RAT," *Chemical Pharmacology*, 43(5):1067-1078, 1992.
	C129	Lum *et al.*, "Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance," *J. Clin. Oncol.*, 10:1635-1642, 1992.
	C130	Mackenzie *et al.*, "Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance," *Clin. Chem. Lab. Med.*, 38(9):889-892, 2000.
SB	C131	Mackenzie *et al.*, "The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence," *Pharmacogenetics*, 7:255-269, 1997.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C132	Magdalou *et al.*, "Peroxisome proliferators as inducers and substrates of UDP-glucuronosyltransferases," *Biol. Cell.*, 77(1):13-16, 1993.
	C133	Makhija *et al.*, "Cytotoxicity of flavopiridol in ovarian cancer cells alone and in combination with CDDP," *Gynecoligic Oncology*, 68(1):83, Abstract #43, 1998.
	C134	Mani and Ratain, "Promising new agents in oncologic treatment," *Curr. Opin. Oncol.*, 8(6):525-534, 1996.
	C135	Manning and Franklin, "Induction of rat UDP-glucuronosyltransferase and glutathione S-transferase activities by L-buthionine-S,R-sulfoximine without induction of cytochrome P-450," *Toxicology*, 65:149-159, 1990.
	C136	Mazzanti *et al.*, "Bile acid inhibition of P-glycoprotein-mediated transport in multidrug-resistant cells and rat liver canalicular membrane vesicles," *Hepatology*, 20(1 Pt 1):170-176, 1994.
	C137	McKinney and Hosford, "ATP-stimulated tetraethylammonium transport by rabbit renal brush border membrane vesicles," *J. Biol. Chem.*, 268(10):6886-6895, 1993.
	C138	Mechetner and Roninson, "Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody," *Proc. Natl. Acad. Sci. USA*, 89(13):5824-5828, 1992.
	C139	Meech and Mackenzie, "Determinants of udp glucuronosyltransferase membrane association and residency in the endoplasmic reticulum," *Arch Biochem Biophys.*, 356:77-85, 1998.
	C140	Michelson and Slate, "A Mathematical Model for the Inhibition of the Multidrug Resistance-Associated P-Glycoprotein Pump," *Bulletin of Mathematical Biology*, 56(2):207-223, 1994.
	C141	Mick *et al.*, "Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of bilary index and intestinal toxicity," *J. Clin. Oncol.*, 14(7):2012-2019, 1996.
	C142	Miki and Kotake, "Advantages in combination chemotherapy using the camptothecin analogue CPT-11 and cisplatinum analogues for human testicular cancer xenografts," *Hinyokika Kiyo*, 39(12):1221-1225, 1993.
	C143	Miller *et al.*, "P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil," *J. Clin. Oncol.*, 9(1):17-24, 1991.
SB	C144	Miners and Mackenzie, "Drug glucuronidation in humans," *Pharmacol Ther.*, 51:347-369, 1991.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C145	Miyamoto *et al*, "Multidrug resistance in yoshida rat ascites hepatoma cell lines" *Anticancer Res.*, 12(3):649-653, 1992.
	C146	Miyamoto *et al.*, "Inhibition of multidrug resistance by a new staurosporine derivative, NA-382, in vitro and in vivo," *Cancer Res.*, 53(7):1555-1559, 1993.
	C147	Miyamoto *et al.*, "Reversal of vinblastine resistance by a new staurosporine derivate, NA-382, in P388/ADR cells" *Cancer Lett.*, 64(2):177-183, 1992a.
	C148	Monaghan *et al.*, "Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome," *Lancet*, 347:578-581, 1996.
	C149	Morris *et al.*, "Interaction of forskolin with the P-glycoprotein multidrug transporter," *Biochemistry*, 30(34):8371-8379, 1991.
	C150	Muller *et al.*, "ATP-dependent transport of amphiphilic cations across the hepatocyte canalicular membrane mediated by mdr1 P-glycoprotein," *FEBS Lett.*, 343(2):168-172, 1994.
	C151	Murthi *et al.*, "Structure-activity relationship studies of flavopiridol analogues," *Bioorganic Med Chem Ltrs*, 10:1037-1041, 2000.
	C152	Nakajima *et al.*, "Involvement of multiple UDP-glucoronosyltransferase 1A isoforms in glucoronidation of 5-(4'-hydroxyphenyl-)-5-phenylhydantoin in human liver microsomes," Drug Metabolism and Disposition, 30(11):1250-1256, 2002.
	C153	Narita *et al.*, "Inhibition of Beta-Glucuronidase by Natural Glucuronides of Kampo Medicines Using Glucuronide of SN-38 (7-ethyl-10-hydroxycamptothecin) as a Substrate," *Xenobiotica*, 23(1):5-10, 1993.
	C154	Nebert, "Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist?" *Clin Gen*, 56:247-258, 1999.
	C155	Negoro *et al.*, "Phase I Study of Weekly Intravenous Infusions of CPT-11, a New Derivative of Camptothecin, in the Treatment of Advanced Non-Small-Cell Lung Cancer," *Journal of the National Cancer Institute*, 83(16):1164-1168, 1991.
SB	C156	Niwa *et al.*, "Effect of a dihydropridine analogue, 2-[benzyl(phenyl)amino]ethyl 1,4-dihydro-2,6-dimethyl-5-(5,5-dimethyl-2-oxo-1,3,2,-dioxaphosphorinan-2-yl)-1-(2-morpholino-ethyl)-4-(3-nitrophenyl)-3-(pyridinecarboxylate on reversing in vivo resistance of tumor cells to adrianmycin[1]," *Cancer Res.*, 52(13):3655-3660, 1992.

25389367.1

EXAMINER:	DATE CONSIDERED: 07/24/2006

/Sarae Bausch/

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C157	Ohe *et al.*, "Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion," *Journal of the National Cancer Institute*, 84(12):972-974, 1992.
	C158	Ohi *et al.*, "Intravesical instillation of adriamycin in the presence or absence of verapamil for the treatment of superficial bladder cancer: preliminary report of a collaborative study," *Cancer Chemother Pharmacol*, 30:S50-S54, 1992.
	C159	Okamura *et al.*, "Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney," *J. Pharmacol. Exp. Therap.*, 266:1614-1619, 1993.
	C160	Owens and Ritter, "Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity and regulation," *Progress in Nucleic Acid Research and Molecular Biology*, 51:305-338, 1995.
	C161	Perdu and Germain, "Identification of novel polymorphisms in the pm5 and mrp1(abcc1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum," *Human Mutation*, 17:74-75, 2001.
	C162	Perez *et al.*, "Mechanisms and Modulation of Resistance to Chemotherapy in Ovarian Cancer," *Cancer Supplement*, 71(4):1571-1580, February 1993.
	C163	Pourtier-Manzanedo *et al.*, "Expression of P-glycoprotein on normal lymphocytes: enhancement of the doxorubicin-sensitivity of concanavalin a –responding mouse spleen cells by P-glycoprotein blockers," *Oncol. Res.*, 4:473-480, 1992.
	C164	Prochaska and Fernandes, "Elevation of serum Phase II enzymes by anticarcinogenic enzyme inducers: markers for a chemoprotected state?," *Carcinogenesis*, 14(12):2441-2445, 1993.
	C165	Purba *et al.*, "The metabolism of 17 α-ethinyloestradiol by human liver microsomes: formation of catechol and chemically reactive metabolites," *Br. J. Clin. Pharmacol.*, 23:447-453, 1987.
	C166	Radominska-Pandya *et al.*, "Human UDP-glucuronosyltransferase 2B7," *Curr. Drug. Metab.*, 2:283-298, 2001.
	C167	Rajaonarison *et. al.*, "In vitro glucuronidation of 3'-azido-3' –deoxythymidine by human liver," *Drug Metab. Disp.*, 19:809-815, 1993.
SB	C168	Ramirez *et al.*, "In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes," *Pharm. Res.*, 19(5):588-594, 2002.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 7/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C169	Ramírez *et al.*,. "In vitro glucuronidation of flavopridol (NSC649890) (flavo) by human liver microsomes," *Clin Pharmacol Ther*, 63:149, Abstract # PI-50, 1998.
	C170	Ratain et al., "Paradoxical relationship between acetylator phenotype and amonafide toxicity," *Clin. Pharmacol. Ther.*, 50:573-579, 1991.
	C171	Ratain, "Irinotecan dosing: does the CPT in CPT-11 stand for "Can't predict toxicity?'" *J. Clin. Oncol.*, 20(1):7-8, 2002.
	C172	Ratain, "Insights into the pharmacokinetics and pharmacodynamics of irinotecan," *Clin. Cancer Res.*, 6:3393-3394, 2000.
	C173	Ritter *et al.*, "A novel complex locus UGT1 encodes human bilirubin, phenol and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini," *J. Biol. Chem.*, 267:3257-3261, 1992.
	C174	Ritter *et al.*, "Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells," *J. Biol. Chem.*, 226:1043-1047, 1991.
	C175	Robert, "Clinical pharmacokinetics of epirubicin," *Clin. Pharmacokinet*, 26:428-438, 1994
	C176	Robey et al., "Overexpression of the atp-binding cassette half-transporter, abcg2 (mxr/bcrp/abcp1), in flavopiridol-resistnat human breast cancer cells," *Clinical Cancer Res.*, 7:145-152, 2001.
	C177	Rothenberg *et al.*, "Phase I and Pharmacokinetic Trial of Weekly CPT-11," *Journal of Clinical Oncology*, 11(11):2194-2204, 1993.
	C178	Rowinsky *et al.*, "Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks," *Cancer Research*, 54:427-436, 1994.
	C179	Rowinsky *et al.*, "Taxol: Pharmacology, Metabolism and Clinical Implications," *Cancer Surv.*, 17:283-304, 1993.
	C180	Rund et al, "A mutation in the promoter of the multidrug resistance gene (mdr1) in human hematological malignancies may contribute to the patogenesis of resistant disease," *Adv. Exp Med Biol.*, 457:71-75, 1999.
SB	C181	Saeki *et al.*, "Human P-Glycoprotein Transports Cyclosporin A and FK506," *The Journal of Biological Chemistry*, 268(9):6077-6080, 1993.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C182	Sakata *et al.*, "Preventive Effect of TJ-14, a Kampo (Chinese herb) Medicine, on Diarrhea Induced by Irinotecan Hydrochloride (CPT-11)," *Gan-To-Kagaku-Ryoho*, 21(8):1241-4, July 1994; Abstract only.
	C183	Samuels *et al.*, "Modulation of vinblastine resistance with cyclosporine: A phase I study," *Clin. Pharmacol. Ther.*, 54:421-429, 1993.
	C184	Sausville et al., "Cyclin-dependent kinases: initial approaches to exploit a novel therapeutic target," *Pharmacol Ther.*, 82:285-292, 1999.
	C185	Schinkel *et al.*, "Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs," *Cell*, 77(4):491-502, 1994.
	C186	Schrenk *et al.*, "Induction of multidrug resistance gene expression during cholestasis in rats and nonhuman primates," *Hepatol.*, 17:854-860, 1993.
	C187	Schrump et al., "Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells," *Clin Cancer Res.*, 4:2885-2890, 1998.
	C188	Senderowicz et al., "Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms," *J Clin Oncol.*, 16:2986-2999, 1998.
	C189	Shapiro et al., "Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines," *Clin. Cancer Res.*, 5:2925-2938, 1999.
	C190	Sherr, "Cancer cell cycles," *Science*, 274:1672-1677, 1996.
	C191	Shirai *et al.*, "Transport of cyclosporin A across the brain capillary endothelial cell monolayer by P-glycoprotein," *Biochim. Biophys. Acta*, 1222(3):400-404, 1994.
	C192	Sinicrope *et al.*, "Modulation of P-glycoprotein-mediated transport by alterations in lipid fluidity of rat liver canalicular membrane vesicles," *J. Biol. Chem.*, 267:24995-25002, 1992.
	C193	Slichenmyer *et al.*, "Camptothecin Analogues: Studies from The Johns Hopkins Oncology Center," *Cancer Chemother. Pharmacol.*, 34:S53-S57, 1994.
	C194	Slichenmyer *et al.*, "The Current Status of Camptothecin Analogues as Antitumor Agents," *Journal of the National Cancer Institute*, 85(4):271-291, February 1993.
SB	C195	Stadler et al., "Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a university of chicago phase II consortium study," *J Clin Oncol.*, 18:371-375, 2000.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Mark J. Ratain *et al.*	
	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C196	Stinson *et al.*, "Determination of flavopiridol (L86 8275; NSC 649890) in human plasma by reversed-phase liquid chromatography with electrochemical detection," *Cancer Chemother. Pharmacol.*, 42(4):261-265, 1998.
	C197	Stocker, "Bilirubin is an antioxidant of possible physiological importance," *Science*, 235:1043-1046, 1987.
	C198	Strassburg *et al.*, "Identification of cyclosporine A and tacrolimus glucuronidation in human liver and the gastrointestinal tract by a differentially expressed UDP-glucuronosyltransferase: UGT2B7," *J. Hepat.*, 34(6):865-872, 2001
	C199	Sugatani *et al.*, "Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia," *Biochem. Biophys. Res. Commun.*, 292(2):492-497, 2002.
	C200	Sugatani *et al.*, "The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR," *Hepatology*, 33(5):1232-1238, 2001.
	C201	Suzuki, "Antitumor drugs and potentiators aiming circumvention of drug resistance," *Jpn J Cancer Chemother*, 17:335-341, 1990.
	C202	Tamai and Safa, "Competitive interaction of cyclosporins with the vinca alkaloid-binding site of P-glycoprotein in multidrug resistant cells," *J. Biol. Chem.*, 265:16509-16513, 1990.
	C203	Taudou *et al.*, "Inhibition of DNA Synthesis and DNA Fragmentation in Stimulated Splenocytes by the Concerted Action of Topoisomerase I and II Poisons," *Biochem. Pharmacol.*, 45(2):331-337, 1993.
	C204	Thalhammer *et al.*, "Bile canalicular cationic dye secretion as a model for P-glycoprotein mediated transport," *Eur. J. Pharmacol.*, 270(2-3):213-220, 1994.
	C205	Thomas *et al.*, "Phase I clincial and pharmacokineti trial of flavopiridol," *Proc Am Assoc Cancer Res*, 38:1496, Abstract #1496, 1997.
	C206	Toide *et al.*, "Hepatocyte nuclear factor 1α is a causal factor responsible for interindividual differences in the expression of UDP-glucuronosyltransferase 2B7 mRNA in humna livers," *Drug Metabolism and Disposition*, 30(6):613-615, 2002.
SB	C207	Trump *et al.*, "High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine," *J. Natl. Cancer Inst.*, 84(23):1811-1816, 1992.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. ARCD:389US	Serial No. 10/751,606
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT	Applicant Mark J. Ratain *et al.*	
(Use several sheets if necessary)	Filing Date: January 5, 2004	Group: 1645

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
SB	C208	Tsuruo *et al.*, "Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors *in vitro* and *in vivo*," *Cancer Chemother. Pharmacol.*, 21:71-74, 1988.
	C209	Tucker, "Clinical implications of genetic polymorphism in drug metabolism," *J. Pharm. Pharmacology*, 46:417-424, 1994.,
	C210	Vezmar and Georges, "Reversal of mrp-mediated doxorubicin resistance with quinoline-based drugs," *Biochem Pharmacol.*, 59:1245-1252, 2000.
	C211	Vore, "Canalicular transport: Discovery of ATP-dependent mechanisms," *Toxicol. Appl. Pharmacol.*, 118:2-7, 1993.
	C212	Wade *et al.*, "Variability in the pharmacokinetics of epirubucin: a population analysis," *Cancer Chemother. Pharmacol.*, 29:391-395, 1992.
	C213	Watanabe *et al.*, "Kinetic Analysis of Hepatobiliary Transport of Vincristine in Perfused," *Journal of Hepatology*, 16:77-88, 1992.
	C214	Wilson *et al.*, "A relationship between multidrug resistance and growth-state dependent cytotoxicity of the lysosomotropic detergent N-dodecylimidazole," *Biochem. Biophys. Res. Commun.*, 176(3):1377-1382, 1991.
	C215	Worland *et al.*, "Alteration of the phosphorylation state of $p34^{cdc2}$ kinase by the flavone L86-8275 in breast carcinoma cells," *Biochem Pharmacol*, 46:1831-1840, 1993.
	C216	Zacherl *et al.*, "Inhibition of P-Glycoprotein-Mediated Vinblastine Transport Across HCT-8 Intestinal Carcinoma Monolayers by Verapamil, Cyclosporine A and SDZ PSC 833 in Dependence on Extracellular pH," *Cancer Chemother. Pharmcol.*, 34:125-132, 1994.
SB	C217	Zhang *et al.*, "Inhibitory Effects of Homoharringtonine and Hydroxycamptothecin in Combination with Other Agents on Cancer Cell Growth," *Asia Pac. J. Pharmacol.*, 7:191-195, 1992.

25389367.1

EXAMINER: /Sarae Bausch/	DATE CONSIDERED: 07/24/2006

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.